Kalytera Therapeutics, Inc.
245 33rd Street
38 articles with Kalytera Therapeutics, Inc.
No Patients Have Developed Grades 3-4 Acute GVHD While Receiving CBD Treatment
Kalytera Therapeutics, Inc. announced that it has entered into an agreement with Beetlebung Pharma, Ltd. ("BPL") for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of both dermatologic diseases and women's health.
Kalytera Therapeutics, Inc. announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,956,182.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the year-ended December 31, 2017. (All dollars U.S. unless otherwise noted.)
Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,889,100 B2 with claims covering the use of cannabidiol ("CBD") for the treatment of severe and refractory graft versus host disease ("GVHD")
Company to Focus Resources on GVHD and Pain Programs
The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant.
Under the deal, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.
The debt owing is in the amount of US$76,000 (or C$94,969.60 based on the daily average exchange rate for January 10, 2018 published by the Bank of Canada).
Kalytera Announces Approval of Shares for Services and Settlement of Debt Transaction With The Salzman Group of Israel
Under the deal, the TSXV has also approved, and the Company has completed, a settlement of certain debts previously owing through the issuance of Common Shares to The Salzman Group.
Kalytera Announces Initiation of Phase II Clinical Study in Prevention of Graft Versus Host Disease and Agreement With The Salzman Group of Israel to Manage and Partially Fund the Study to be Led by a World Class Team
The Phase 2 study is designed to assess the pharmacokinetic and safety profile of multiple doses of CBD for the prevention of GVHD.
The company confirms that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
Kalytera’s Phase 2 study is expected to enroll 36 patients following allogeneic hematopoietic cell transplantation ("HCT"), commonly referred to as bone marrow transplantation.
Securing a patent for this proprietary technology represents an important step forward for the Company in its work focused on the treatment of this serious and life-threatening disease.
Kalytera Receives IRB Approval For Proposed Phase II Study Evaluating CBD In The Prevention Of Graft Versus Host Disease
Kalytera Submits Phase II Study Protocol To Irbs For Cannabidiol In The Prevention Of Graft Versus Host Disease